Project Grant R01HL174555
Award Date 9/1/25
Completion Date 6/30/30
Dollars Obligated $694K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,568.00 to The Leland Stanford Junior University (Stanford University) to conduct research aimed at disaggregating and spatially profiling early-stage lung fibrosis microenvironments. The overarching goal is to utilize spatial biology and biomaterial modeling techniques to uncover the cellular and molecular drivers of early fibrogenesis in interstitial...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $722,667 project grant to the University of Texas Health Science Center at Houston (UTHealth) to conduct research on ribosome dysfunction in lung fibrosis associated with systemic sclerosis (SSc). The 5-year project, spanning from September 1, 2025 to May 31, 2030, aims to investigate the mechanisms by which enhanced ribosome biogenesis leads to an altered...
- This federal Project Grant award of $644,997.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify proteomic biomarkers that can predict the progression of idiopathic pulmonary fibrosis (IPF), a severe and often fatal lung disease. The research aims to develop non-invasive assessments that can identify individuals at higher risk of developing IPF and those with more progressive forms of the disease, enabling earlier...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,498,380 to Yale University to conduct research on the role of mitochondrial DNA and sex differences in scleroderma-associated interstitial lung disease (SSC-ILD). The research aims to elucidate how differential interactions between extracellular mitochondrial DNA and the Toll-like receptor 9 (TLR9) drive sexual dimorphism in SSC-ILD. Key objectives include...
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This Project Grant award of $108,003.00, provided by the National Heart Lung and Blood Institute under CFDA Program 93.837 Cardiovascular Diseases Research, supports a study on "Early Changes of T2* Measures in Lung Tissues Using Deltate-UTE MRI on Healthy and COPD Patients" at the University of California, San Diego (UCSD). The goal is to develop an advanced ultrashort echo-time (UTE) magnetic resonance imaging (MRI) technique, called TE-UTE, to accurately map T2* values in lung...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,659,996.00 to the University of Southern California (USC) to investigate the role of the NF-kappaB modulator PDLIM2 in alveolar macrophages and its impact on lung innate immunity, inflammation, and diseases. The research aims to elucidate how alveolar macrophages, which are critical for lung defense, can promote lung cancer and increase vulnerability to...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...